501673-86-5

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]amino]-, 1,1-dimethylethyl ester
• CAS NO: 501673-86-5
• Molecular Formula: C17H23F3N2O3
• Molecular Weight: 360.376
• Mol File: 501673-86-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]amino]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]amino]-, 1,1-dimethylethyl ester(501673-86-5)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[[4-(trifluoromethoxy)phenyl]amino]-, 1,1-dimethylethyl ester(501673-86-5)

Safety Data

• Hazardous Substances Data: 501673-86-5(Hazardous Substances Data)

Upstream product

• 461-82-5 4-(trifluoromethoxy)aniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 681482-48-4 N-(4-(trifluoromethoxy)phenyl)piperidine-4-amine 
• 501673-90-1 1-(tert-butoxycarbonyl)-4-[N-[(4-trifluoromethoxy)phenyl]-N-[3-(3,4,5-trimethoxyphenyl)benzyl]amino]piperidine 
• 501673-88-7 1-(tert-Butoxycarbonyl)-4-[N-[4-(trifluoromethoxy)phenyl]-N-[[3-(3,4,5-trimethoxyphenyl)pyridin-5-yl]methyl]amino]piperidine 
• 1350809-11-8 C₂₅H₂₈F₃N₃O₃ 
• 1350808-98-8 C₂₄H₂₉F₃N₂O₃ 
• 1350809-26-5 C₂₀H₂₀F₃N₃O 
• 1350809-15-2 C₁₉H₂₁F₃N₂O 

Relevant articles and documents

(6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

(6,7-Dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the descriptio

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

ERYTHROPOIETIN PRODUCTION ACCELERATOR

The present invention relates to a preventive or therapeutic agent for pathological conditions caused by reduced production of erythropoietin, or for anemia, or for chronic anemia, renal anemia, aplastic anemia, or pure red cell aplasia, the agent comprising, as an active ingredient, a cyclic amine compound represented by the following formula (1): wherein, ???R1, R2 and R3 each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group; ???W1 and W2 each independently represent N or CH; ???X represents O, NR4, CONR4 or NR4CO; ???R4 each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and ???l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof.